



Fatty liver index has potential as a predictor of hypertension in the Japanese general population

Naoki Nakagawa¹

Keywords Fatty liver · Blood pressure · Glycemia

Received: 8 January 2023 / Accepted: 18 January 2023 / Published online: 7 February 2023
© The Author(s), under exclusive licence to The Japanese Society of Hypertension 2023

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide and the leading cause of liver-related morbidity and mortality [1]. Emerging evidence has shown that NAFLD is strongly associated with an increased risk of incident hypertension and cardiovascular diseases [2, 3]. However, the role of NAFLD in the development of hypertension is still unclear and is highly overlooked by the general public. Although the gold standard test to diagnose fatty liver is liver biopsy, fatty liver is usually diagnosed by imaging tests, such as abdominal ultrasound in clinical practice. Another method used to assess fatty liver is the fatty liver index (FLI), which is based on body mass index (BMI), waist circumference (WC), fasting serum triglycerides (TG), and gamma-glutamyl transferase (GGT) [4], and its utility has been proven. Several studies have reported FLI as a good predictor of incident hypertension; [5, 6] however, whether this applies in the absence of dysglycemia has yet to be determined.

In the current issue of *Hypertension Research*, Wu et al. [7] reported an observational study to determine whether FLI was independently associated with an increased risk of incident hypertension in individuals with and without dysglycemia. In their study, Wu et al. [7] enrolled 3114 patients (1036 males and 2078 females) without hypertension who underwent a Specific Health Checkup in the fiscal year 2013 and were followed up until 2018. They evaluated the incidence of hypertension by dividing the participants into six groups based on FLI tertiles (low, moderate, or high) and

whether they had dysglycemia. During the mean follow-up period of 2.8 years, 160 of the 3114 participants developed hypertension. Using the low FLI group with normoglycemia as a reference, the hazard ratio (HR) for incident hypertension was increased in the high FLI group with and without dysglycemia in both sexes after adjusting for confounders except systolic blood pressure (SBP), HR [95% confidence interval (CI)]: male: 1.52 [1.06–2.07] in normoglycemia and 2.05 [1.43–2.92] in dysglycemia, and female: 1.86 [1.43–2.42] in normoglycemia and 2.98 [2.19–4.07] in dysglycemia (Fig. 1). After adjusting for SBP, the risk of developing hypertension was no longer significant in males in the high FLI group with normoglycemia (HR [95% CI]: 1.27 [0.89–1.81]). Meanwhile, it remained unchanged in females in the high FLI group with normoglycemia (HR [95% CI]: 1.51 [1.16–1.98]) and both males and females (male: 1.60 [1.12–2.28] and female: 2.20 [1.61–3.00]) in the high FLI groups with dysglycemia. It is




Fig. 1 Hazard ratios and 95% confidence intervals of fatty liver index tertile groups with and without dysglycemia for the development of hypertension which was demonstrated by Wu et al. [7]. CI confidence interval, FLI fatty liver index

✉ Naoki Nakagawa
naka-nao@asahikawa-med.ac.jp

¹ Division of Cardiology, Nephrology, Pulmonology, and Neurology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Japan

interesting to note that the hazard ratio is consistently higher for females than for males.

As for the mechanism by which NAFLD causes hypertension, NAFLD may promote hypertension by (1) initiating systemic inflammation via secreted cytokines, (2) inducing insulin resistance, which are critical pathophysiological mechanisms leading to the development of hypertension by increasing vasoconstriction and water-sodium retention, (3) increasing oxidative stress in accelerated vascular aging in hypertension, (4) directly increasing vasoconstriction and decreasing vasodilation via increased levels of circulating asymmetrical dimethylarginine, which is an endogenous inhibitor of nitric oxide synthase [1]. Given the close association between NAFLD and hypertension, much attention should be paid to the overlapping management approaches. At present, the fundamental management approach for both NAFLD and hypertension focuses on lifestyle modifications, including consuming a healthy balanced diet, weight reduction, and regular physical activity [1, 8]. Therefore, FLI might be a useful predictor of hypertension in the Japanese general population regardless of the presence of dysglycemia, as described by Wu et al. [7].

Furthermore, Wu et al. [7] did not adopt the conventional classification of $FLI \geq 60$ or $FLI < 30$, which is used in most studies of Westerners [9] but adopted tertiles of FLI by gender. Although the prevalence of obesity is lower in Asians than in other ethnic groups, the prevalence of fatty liver is not lower [10]. Therefore, in Asian populations, the cut-off values for FLI to identify fatty liver may be lower than in other ethnic groups, e.g., $FLI \geq 35$ in men and $FLI \geq 20$ in women in Taiwan [11]. As a result, they found that higher FLI, even if the cut-off values are lower than the conventional values, is associated with an increased risk for the development of hypertension in Asians. Further studies will be needed to determine the optimal cut-off value of FLI in Asian populations for predicting the development of hypertension and cardiovascular diseases.

In conclusion, the study of Wu et al. on Japanese community dwellers showed that higher FLI was associated with an increased risk of the development of hypertension among individuals with or without dysglycemia, suggesting that those with high FLI, even if normoglycemic, should be managed for the prevention of hypertension. Future studies are needed to assess the association between higher FLI and the development of hypertension and cardiovascular

diseases for healthy longevity in the Japanese general population.

Compliance with ethical standards

Conflict of interest The author declares no competing interests.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

- Zhao YC, Zhao GJ, Chen Z, She ZG, Cai J, Li H. Nonalcoholic fatty liver disease: an emerging driver of hypertension. *Hypertension*. 2020;75:275–84.
- Stranges S, Trevisan M, Dorn JM, Dmochowski J, Donahue RP. Body fat distribution, liver enzymes, and risk of hypertension: evidence from the Western New York Study. *Hypertension*. 2005;46:1186–93.
- Siafi E, Andrikou I, Thomopoulos C, Konstantinidis D, Kakouri N, Tatakis F, et al. Fatty liver index and cardiovascular outcomes in never-treated hypertensive patients: a prospective cohort. *Hypertens Res*. 2023;46:119–27.
- Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. *BMC Gastroenterol*. 2006;6:33.
- Higashiura Y, Furuhashi M, Tanaka M, Takahashi S, Mori K, Miyamori D, et al. Elevated fatty liver index is independently associated with new onset of hypertension during a 10-year period in both male and female subjects. *J Am Heart Assoc*. 2021;10:e021430.
- Zhou K, Cen J. The fatty liver index (FLI) and incident hypertension: a longitudinal study among Chinese population. *Lipids Health Dis*. 2018;17:214.
- Wu D, Hirata A, Hirata T, Imai Y, Kuwabara K, Funamoto M, et al. Fatty liver index predicts the development of hypertension in a Japanese general population with and without dysglycemia. *Hypertens Res*. <https://doi.org/10.1038/s41440-022-01161-2>. 2023. Online ahead of print.
- Nakagawa N, Hasebe N. Impact of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines on the Next Blood Pressure Guidelines in Asia. *Curr Hypertens Rep*. 2019;21:2.
- Jager S, Jacobs S, Kroger J, Stefan N, Fritsche A, Weikert C, et al. Association between the fatty liver index and risk of type 2 diabetes in the EPIC-Potsdam study. *PLoS ONE*. 2015;10:e0124749.
- Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: disparate associations among Asian populations. *World J Hepatol*. 2014;6:263–73.
- Yang BL, Wu WC, Fang KC, Wang YC, Huo TI, Huang YH, et al. External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan. *PLoS ONE*. 2015;10:e0120443.